Key Highlights

  • Revenue was USD 8.9 million, up 20% year over year, against a USD 9.60 million estimate.
  • System Revenue rose to USD 3.0 million from USD 1.9 million, while Recurring Revenue of USD 5.9 million rose 6%.
  • Gross Margin was 45%, and cash and cash equivalents were USD 4.0 million before the financing.
  • The company announced up to USD 24 million of convertible notes, including USD 12 million at the initial closing.

Stereotaxis (NYSE:STXS), a surgical robotics company focused on minimally invasive endovascular intervention, reported third quarter 2026 revenue of USD 8.9 million, below the USD 9.60 million estimate. Revenue rose 20% from USD 7.5 million a year earlier and 16% from USD 7.7 million in the second quarter. Loss per share was USD 0.07 against an estimated loss of USD 0.05.

System revenue was USD 3.0 million against USD 1.9 million, and management said robotic Capital revenue rose over 20% sequentially. Recurring revenue was USD 5.9 million, up 6% from a year earlier and down 4% from the second quarter, which the company linked to Supply shortages that pressured procedures.

Margins, Expenses and Losses

Gross margin was 45% of revenue, with recurring revenue at 59% and system revenue at 15%. Operating expenses were USD 10.4 million, including USD 1.3 million of non-cash charges. Adjusted operating expenses were USD 9.1 million against USD 6.6 million, which the company attributed to one-time Acquisition Transaction Costs and the absorption of Robocath operating expense.

Net loss was USD 6.5 million, the same as a year earlier. Adjusted net loss was USD 5.2 million against USD 2.4 million. Negative cash flow was USD 6.5 million, of which USD 2.6 million related to the core Business and USD 3.9 million to payments for the Robocath acquisition.

Convertible Note Financing

The company announced definitive agreements for a convertible note financing of up to USD 24 million, with USD 12 million at the initial closing and another USD 12 million available at its option following certain regulatory milestones. The notes carry 10% annual interest, accrued and due at Maturity in three years, and convert at USD 1.21 per share, a 30% premium to the prior 10-day Volume weighted average price.

Cash and cash equivalents were USD 4.0 million at September 30. Including the financing, pro forma cash is USD 16 million, with access to another USD 12 million, for total availability of USD 28 million.

Supply, Guidance and Items to Follow

Management cited a Backlog of about USD 1.9 million of disposable orders that could not be converted to revenue because of supply constraints, and said it sees an opportunity for the shortage to be resolved in early 2027. It guided adjusted operating expenses of about USD 8 million per quarter and said growth in revenue with stable spending provides a pathway to cash-flow profitability within the next year.

The items to follow are the first commercial GenesisX installations, resolution of supply constraints for MAGiC catheters, the Robocath integration, the Canon collaboration and conversion of the note financing.